Compare · ABSI vs ISPC
ABSI vs ISPC
Side-by-side comparison of Absci Corporation (ABSI) and iSpecimen Inc. (ISPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and ISPC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI is the larger of the two at $1.52B, about 587.5x ISPC ($2.6M).
- Over the past year, ABSI is up 71.5% and ISPC is down 97.0% - ABSI leads by 168.6 points.
- ABSI has been more active in the news (5 items in the past 4 weeks vs 3 for ISPC).
- ABSI has more recent analyst coverage (21 ratings vs 2 for ISPC).
PerformanceABSI+71.52%ISPC-97.03%
2025-10-20+0.00%2026-10-16
- Company
- Absci Corporation
- iSpecimen Inc.
- Price
- $8.25-7.09%
- $0.95-7.32%
- Market cap
- $1.52B
- $2.6M
- 1M return
- -10.86%
- -29.10%
- 1Y return
- +71.52%
- -97.03%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 5
- 3
- Recent ratings
- 21
- 2
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 2% to 483,144 units (SEC Form 4) (withholding obligation)
- Absci to Participate in Upcoming Investor Conferences
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
Latest ISPC
- SEC Form PRER14A filed by iSpecimen Inc.
- SEC Form 8-K filed by iSpecimen Inc.
- iSpecimen Supports Hospital Validation of New Chemistry Analyzer
- SEC Form DEF 14A filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form PRE 14A filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits